Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Replacing glucocorticoids in primary adrenal insufficiency (AI) or Addison's disease (AD) is today based on oral replacement therapy with hydrocortisone in a conventional immediate-release tablet. It is recognised that physiological gastrointestinal factors may have a strong influence on the plasma concentration-time profile of hydrocortisone. Hydrocortisone has a sufficiently high permeability in both the small and large intestine, but in vivo dissolution from the available oral product is limited at higher doses. The short elimination half-life of hydrocortisone (approximately 1.5 h) when given in traditional immediate-release dosage forms requires two or more dose administrations per day, with high peaks and low trough values in between. The endogenous secretion of cortisol from the adrenal cortex follows a distinct diurnal pattern, with increasing and high plasma levels of cortisol early in the morning (approximately 05.00-08.00 h), intermediate levels in the afternoon, low levels in the evening and a cortisol-free interval at night. There is, therefore, a clinical need for an improved drug delivery product that more closely follows the circadian pattern of cortisol in plasma. OBJECTIVE: The pharmaceutical and biopharmaceutical properties of the dosage form containing hydrocortisone will determine intestinal absorption rate and the plasma concentration-time profile of hydrocortisone (cortisol). Factors that cause or result in pharmacokinetic variability should be understood and avoided where possible. METHODS: A literature search was performed with the aim of covering the field of gastrointestinal drug absorption of hydrocortisone in AD. RESULTS/CONCLUSION: Novel oral drug delivery principles for facilitation of once-daily dosing and providing a safe and physiologically based plasma concentration-time profile of hydrocortisone in replacement therapy are discussed. Development of new drug formulations is ongoing and will certainly lead to an improved replacement therapy of AD with hydrocortisone. Of special interest is a therapy based on once-daily treatment and less fluctuating plasma concentrations of hydrocortisone (cortisol).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · cited 9×
“The highly fluctuating plasma concentrations of cortisol after oral immediaterelease cortisol are also expected to provide unphysiological fluctuation in many of the pleitropic effects [11,34] .”
BackgroundMethodInfluentialArlt, W., & Allolio, B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13492-7 · Cited by 819
Premature Mortality in Patients with Addison’s Disease: A Population-Based Study
Bergthorsdottir, R., Leonsson-Zachrisson, M., Odén, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0076 · Cited by 490 · cited 4×
“(2008) 4(6) also the delivery rate to mimic the circadian serum steroid concentration-time profile [8,9] .”
BackgroundSelf-citationDaily cortisol production rate in man determined by stable isotope dilution/mass spectrometry
ESTEBAN, N. V., LOUGHLIN, T., YERGEY, A. L., ZAWADZKI, J. K., BOOTH, J. D., WINTERER, J. C., & LORIAUX, D. L. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-39 · Cited by 481 · cited 3×
“The plasma profile of hydrocortisone after a single dose of 20 mg Duocort administered in the early morning on an empty stomach resembles the endogenous profile of cortisol ( Figure 3 ) [10,38-40] .”
BackgroundMethodFilipsson, H., Monson, J. P., Koltowska-Häggström, M., Mattsson, A., & Johannsson, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0524 · Cited by 321 · cited 1×
“Recently, it has been observed that there is a link between unphysiological and overly high dose of glucocortiocoid therapy and poor cardiovascular risk profile, with abdominal obesity and an atherogenic lipid profile [36] .”
BackgroundSelf-citationMah, P. M., Jenkins, R. C., Rostami‐Hodjegan, A., Newell‐Price, J., Doane, A., Ibbotson, V., Tucker, G. T., & Ross, R. J. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02106.x · Cited by 243 · cited 5×
“The C max in plasma and serum of hydrocortisone has been reported to be about 550 – 650 nM in the fasted state when measured with an immunoassay method [32] .”
BackgroundMethodInfluentialGlucocorticoid replacement therapy: are patients over treated and does it matter?
Peacey, S. R., Guo, C., Robinson, A. M., Price, A., Giles, M. A., Eastell, R., & Weetman, A. P. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.780907.x · Cited by 205
Cortisol production rate in childhood and adolescence
Linder, B. L., Esteban, N. V., Yergey, A. L., Winterer, J. C., Loriaux, D. L., & Cassorla, F. (1990) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80128-3 · Cited by 202 · cited 4×
“(2008) 4(6) glands (the hypothalamic-pituitary-adrenal axis, HPA) [1-3] .”
MethodInfluentialAn assessment of optimal hydrocortisone replacement therapy
Howlett, T. A. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1340955.x · Cited by 169 · cited 3×
“Based on arbitrarily defined optimal serum levels of cortisol, 60% of patients receiving HC three times a day (10, 5 and 5 mg) have an acceptable daytime serum cortisol profile compared with 15% of those on a twice-daily regimen [33] .”
BackgroundInfluentialMerza, Z., Rostami‐Hodjegan, A., Memmott, A., Doane, A., Ibbotson, V., Newell‐Price, J., Tucker, G. T., & Ross, R. J. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02544.x · Cited by 98
Cited by
Johannsson, G., Bergthorsdottir, R., Nilsson, A. G., Lennernas, H., Hedner, T., & Skrtic, S. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0170 · Cited by 173
Self-citationAdrenal insufficiency: etiology, diagnosis and treatment
Neary, N., & Nieman, L. (2010) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e328338f608 · Cited by 140
Whitaker, M. J., Debono, M., Huatan, H., Merke, D. P., Arlt, W., & Ross, R. J. (2014) · Clinical Endocrinology · doi:10.1111/cen.12316 · Cited by 121
Grossman, A., Johannsson, G., Quinkler, M., & Zelissen, P. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0450 · Cited by 119
Self-citationSleep, cognition and cortisol in addison’s disease: a mechanistic relationship
Henry, M., Thomas, K. G. F., & Ross, I. L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694046 · Cited by 34
Metadata
- Authors
- Lennernäs, H., Skrtic, S., & Johannsson, G.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2008-06
- Volume
- 4
- Issue
- 6
- Pages
- 749-758
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2151378185
- Cited by
- 25
- References
- 10
- FWCI
- 1.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.